Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanobody-based Biepitope BCMA CAR-T in R/R Multiple Myeloma
NCT06503107Phase 2Recruiting
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells, Nanobodies (VHH)
- Countries
- 1
01
Overview
A Phase 2 trial of nanobody-based biepitope BCMA-targeting CAR-T cells in multiple myeloma (MM). Started Apr 2024; status: recruiting.
02
Drugs
nanobody-based biepitope BCMA-targeting CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06503107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06503107.